Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

To be considered for this study, you must have a confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer. It's crucial that your cancer has the specific EGFR exon 20 insertion mutation, which your doctors will have tested for in your tumour tissue or blood. Your cancer must also not be suitable for treatment with surgery or radiotherapy that would be intended to cure it.

This study is for people who have not yet received any previous treatment specifically for their advanced lung cancer. If you had chemotherapy, immunotherapy, or radiotherapy for lung cancer that hadn't spread (non-metastatic disease) in the past, you might still be eligible, but there needs to have been at least a 12-month break since your last treatment.

Even if you have had brain metastases (where the cancer has spread to the brain), you might still be able to join. This applies if they've been treated and are stable, or if they're new but not causing any symptoms. You must be at least 18 years old to participate.

If you decide to join this study, you will be randomly assigned to one of three treatment groups. This is like drawing lots, to ensure fairness. You could receive furmonertinib (an oral tablet) at one of two daily doses, or standard platinum-based chemotherapy given intravenously (into a vein). Your doctor and the study team will explain exactly what your specific treatment involves.

Taking part will involve regular hospital visits for assessments, which will include physical examinations, blood tests, and scans (like CT scans) to monitor your treatment and see how the cancer is responding. The frequency and duration of these visits will depend on which treatment group you are in and how you are responding. You will have ongoing follow-up with the study team to monitor your health and any side effects. The total duration of your participation will vary depending on your individual response to treatment and will be explained in detail by the study team.